Bladder cancer in cats and dogs

FerGene to Present Bladder Cancer Data at 2020 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Monday, February 10, 2020

FerGene, a newly created gene therapy company committed to revolutionizing the treatment of bladder cancer, today announced it will present research at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium taking place February 13-15 in San Francisco, California.

Key Points: 
  • FerGene, a newly created gene therapy company committed to revolutionizing the treatment of bladder cancer, today announced it will present research at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium taking place February 13-15 in San Francisco, California.
  • The virus is designed to enter the cells of the bladder wall, where it breaks down, releasing the active gene to do its work.
  • This novel gene therapy approach thereby uses the patients own bladder wall cells to produce interferon, enhancing the bodys natural defenses against the cancer.
  • 5 Cookson, M et al., Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.